LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.
From the U.S. FDA-approved label for Chlorambucil. Full label: DailyMed.
LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.
From the U.S. FDA-approved label for Chlorambucil. Full label: DailyMed.
The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient. The entire daily dose may be given at one time.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. Patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. There may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Because of its carcinogenic properties, chlorambucil should not be given to patients with conditions other than chronic lymphatic leukemia or malignant lymphomas. Convulsions, infertility, leukemia, and secondary malignancies have been observed when chlorambucil was employed in the therapy of malignant and non-malignant diseases. There are many reports of acute leukemia arising in patients with both malignant and non-malignant diseases following chlorambucil treatment. In many instances, these patients also received other chemotherapeutic agents or some form of radiation therapy.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
To report SUSPECTED ADVERSE REACTIONS, contact Waylis Therapeutics LLC Toll-Free at 1-888-514-4727 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Hematologic The most common side effect is bone marrow suppression, anemia, leukopenia, neutropenia, thrombocytopenia, or pancytopenia. Although bone marrow suppression frequently occurs, it is usually reversible if the chlorambucil is withdrawn early enough.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
7 products from 3 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Celkeran 2 Tablet | Chlorambucil (2mg) | Celon Laboratories Ltd | strip of 30 tablets |
| Celkeran 5mg Tablet | Chlorambucil (5mg) | Celon Laboratories Ltd | strip of 30 tablets |
| Chloramax 2mg Tablet | Chlorambucil (2mg) | GLS Pharma Ltd. | bottle of 30 tablets |
| Chloramax 5 Tablet | Chlorambucil (5mg) | GLS Pharma Ltd. | bottle of 30 tablets |
| Clokeran 2 Tablet | Chlorambucil (2mg) | Natco Pharma Ltd | strip of 30 tablets |
| Clokeran 5mg Tablet | Chlorambucil (5mg) | Natco Pharma Ltd | strip of 30 tablets |
| Radix AQ 5mg Tablet | Chlorambucil (5mg) | GLS Pharma Ltd. | strip of 30 tablets |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store in a refrigerator, 2° to 8°C (36° to 46°F).
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
